Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase

被引:8
|
作者
Ge, GX [1 ]
Wu, J [1 ]
Wang, Y [1 ]
Lin, QS [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China
关键词
epidermal growth factor (EGF); EGF receptor; receptor tyrosine kinase; activation; mechanism;
D O I
10.1006/bbrc.2001.6285
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dimerization of epidermal growth factor receptor (EGFR) leads to the activation of its tyrosine kinase. To elucidate whether dimerization is responsible for activation of the intracellular tyrosine kinase domain or just plays a role in the stabilization of the active form, the activated status of wild-type EGFR moiety in the heterodimer with kinase activity-deficient mutant receptors was investigated. The kinase activity of the wildtype EGFR was partially activated by EGF in the heterodimer with intracellular domain deletion (sEGFR) or ATP binding-deficient mutant (K721A) EGFRs, while the wild-type EGFR in the heterodimer of wild-type and phosphate transfer activity-deficient mutant receptor D813N could be fully activated. After treatment with EGF, the ATP binding affinity and the V-max of the wildtype EGFR increased. In the presence of sEGFR, a similar increase in the affinity for ATP was observed, but V-max did not change. A two-step activation mechanism for EGFR was proposed: upon binding of EGF, the affin -ity for ATP increased and then, as a result of interaction between the neighboring tyrosine kinase domain, V-max increased. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:914 / 920
页数:7
相关论文
共 50 条
  • [21] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Depression Reply
    Morgan, Jeffrey A.
    Quek, Richard
    George, Suzanne
    Block, Susan D.
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : E51 - E51
  • [22] Pharmacophore analysis of epidermal growth factor receptor tyrosine kinase inhibitors
    Peng, T
    Pei, JF
    Zhou, JJ
    ACTA CHIMICA SINICA, 2003, 61 (03) : 430 - 434
  • [23] Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
    Raymond, E
    Faivre, S
    Armand, JP
    DRUGS, 2000, 60 (Suppl 1) : 15 - 23
  • [24] Evaluation of Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    James M. Rae
    Marc E. Lippman
    Breast Cancer Research and Treatment, 2004, 83 : 99 - 107
  • [25] Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    Pallis, A. G.
    Syrigos, K. N.
    LUNG CANCER, 2013, 80 (02) : 120 - 130
  • [26] Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor
    Liechti, C
    Séquin, U
    Bold, G
    Furet, P
    Meyer, T
    Traxler, P
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2004, 39 (01) : 11 - 26
  • [27] Thermal inactivation of the protein tyrosine kinase of the epidermal growth factor receptor
    Stein, RA
    Staros, JV
    BIOCHEMISTRY, 1996, 35 (09) : 2878 - 2884
  • [28] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents
    Fortunato Ciardiello
    Drugs, 2000, 60 : 25 - 32
  • [29] CALMODULIN INHIBITS THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE
    SANJOSE, E
    BENGURIA, A
    GELLER, P
    VILLALOBO, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1992, 267 (21) : 15237 - 15245
  • [30] Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
    Rukazenkov, Yuri
    Speake, Georgina
    Marshall, Gayle
    Anderton, Judith
    Davies, Barry R.
    Wilkinson, Robert W.
    Hickinson, D. Mark
    Swaisland, Alan
    ANTI-CANCER DRUGS, 2009, 20 (10) : 856 - 866